Back to Search
Start Over
A UK multicentre audit of the management of patients with primary hypercholesterolaemia or mixed dyslipidaemia with bempedoic acid against published lipid-lowering treatment targets
- Source :
- Drugs in Context, Vol 13, Pp 1-11 (2024)
- Publication Year :
- 2024
- Publisher :
- BioExcel Publishing Ltd, 2024.
-
Abstract
- Background: Bempedoic acid, an adenosine triphosphate citrate lyase inhibitor, was introduced to UK practice via a pre-reimbursement access scheme for adults with primary hypercholesterolaemia or mixed dyslipidaemia who are at high risk of cardiovascular disease, in whom statins are either not tolerated or contraindicated, who have not achieved target cholesterol, despite being on ezetimibe therapy, and do not qualify for PCSK9 inhibitor treatment. This retrospective multicentre audit aimed to evaluate the achievement of lipid-lowering targets with bempedoic acid in UK patients based on recommendations in the Joint British Societies (JBS) guidelines for the prevention of cardiovascular disease. Methods: Pseudo-anonymized medical record data for 221 adults treated with bempedoic acid as part of the UK scheme were entered into a bespoke data collection tool at four UK hospitals. Patient demographics, clinical characteristics, treatment pathways and lipid assessment results (against JBS lipid-lowering targets) were collected against pre-specified criteria. Results: Overall, 54% (99/184) of patients achieved the JBS2 audit standard (total cholesterol (TC)
Details
- Language :
- English
- ISSN :
- 17404398
- Volume :
- 13
- Database :
- Directory of Open Access Journals
- Journal :
- Drugs in Context
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.9f6774c74e7c4137841acfb2c7b85d94
- Document Type :
- article
- Full Text :
- https://doi.org/10.7573/dic.2024-2-4